Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CYCC |
---|---|---|
10:06 ET | 100 | 2.03 |
10:33 ET | 100 | 2.02 |
10:44 ET | 6429 | 2.03 |
10:48 ET | 166 | 2.025 |
10:53 ET | 4542 | 2 |
10:57 ET | 1175 | 2.049 |
11:02 ET | 200 | 2.04 |
11:06 ET | 1000 | 2.0381 |
11:08 ET | 181 | 2.0496 |
11:49 ET | 300 | 2.025 |
11:56 ET | 999 | 2.01 |
12:25 ET | 155 | 2.0171 |
12:52 ET | 145 | 2.0291 |
01:12 ET | 293 | 1.9901 |
01:15 ET | 100 | 2.02 |
01:21 ET | 100 | 2 |
01:30 ET | 800 | 2.03 |
02:00 ET | 600 | 2 |
03:18 ET | 22273 | 2.1 |
03:20 ET | 900 | 2.0999 |
03:21 ET | 2300 | 2.04 |
03:23 ET | 2400 | 2.09 |
03:25 ET | 5000 | 2.0999 |
03:27 ET | 234639 | 2.48 |
03:30 ET | 47671 | 2.5101 |
03:32 ET | 167658 | 2.8 |
03:34 ET | 190172 | 2.82 |
03:36 ET | 144786 | 2.817 |
03:38 ET | 272809 | 2.8001 |
03:39 ET | 161106 | 2.71 |
03:41 ET | 137973 | 2.6192 |
03:43 ET | 59209 | 2.57 |
03:45 ET | 65670 | 2.59 |
03:48 ET | 155895 | 2.72 |
03:50 ET | 72459 | 2.68 |
03:52 ET | 29828 | 2.67 |
03:54 ET | 59253 | 2.7001 |
03:56 ET | 67486 | 2.7699 |
03:57 ET | 57380 | 2.7 |
03:59 ET | 18342 | 2.64 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Cyclacel Pharmaceuticals Inc | 3.0M | -0.1x | --- |
Manuka Inc | 3.4M | -2.4x | --- |
Aditxt Inc | 3.2M | 0.0x | --- |
Lipella Pharmaceuticals Inc | 4.8M | -0.8x | --- |
Regen BioPharma Inc | 4.1M | -4.4x | --- |
Palisade Bio Inc | 4.3M | -0.2x | --- |
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The epigenetic/anti-mitotic program is evaluating plogosertib, in solid tumors and hematological malignancies. The Company's Plogosertib is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in solid tumor and hematological malignancy indications.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.0M |
---|---|
Revenue (TTM) | $449.0K |
Shares Outstanding | 1.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.52 |
EPS | $-21.99 |
Book Value | $0.57 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | 6.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -5,008.69% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.